WO1993019178A3 - Peptides utilises pour l'induction de tolerance - Google Patents

Peptides utilises pour l'induction de tolerance Download PDF

Info

Publication number
WO1993019178A3
WO1993019178A3 PCT/US1993/002462 US9302462W WO9319178A3 WO 1993019178 A3 WO1993019178 A3 WO 1993019178A3 US 9302462 W US9302462 W US 9302462W WO 9319178 A3 WO9319178 A3 WO 9319178A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
seq
peptides
inducing tolerance
peptides useful
Prior art date
Application number
PCT/US1993/002462
Other languages
English (en)
Other versions
WO1993019178A2 (fr
Inventor
Malcolm L Gefter
Richard D Garman
Julia L Greenstein
Mei-Chang Kuo
Thomas J Briner
Malcolm Morville
Original Assignee
Immunologic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunologic Pharma Corp filed Critical Immunologic Pharma Corp
Priority to JP5516715A priority Critical patent/JPH07505365A/ja
Priority to AU39226/93A priority patent/AU677954B2/en
Priority to CA2132873A priority patent/CA2132873C/fr
Priority to EP93908385A priority patent/EP0672134A1/fr
Publication of WO1993019178A2 publication Critical patent/WO1993019178A2/fr
Publication of WO1993019178A3 publication Critical patent/WO1993019178A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)

Abstract

L'invention se rapporte à la découverte que l'administration par injection sous-cutanée d'un peptide comprenant au moins un épitope de lymphocyte T d'une protéine allergène ou d'une autre protéine antigénique rend les lymphocytes T tolérants après exposition ultérieure à l'allergène ou à l'autre antigène. L'invention concerne également les peptides utilisés pour induire une tolérance chez un mammifère tel que l'être humain par administration sous-cutanée ou autre. Ces peptides comprennent: le peptide X (Nº ID SEQ: 7), peptide Y (Nº ID SEQ: 8), peptide X (Nº ID SEQ: 9), peptide A (Nº ID SEQ: 10), peptide B (Nº ID SEQ: 11), peptide C (Nº ID SEQ: 12), peptide D (Nº ID SEQ: 13), et peptide E (Nº ID SEQ: 14), chacun étant représenté dans la figure. Il est préférable que ces peptides soient administrés sous forme soluble.
PCT/US1993/002462 1992-03-25 1993-03-25 Peptides utilises pour l'induction de tolerance WO1993019178A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP5516715A JPH07505365A (ja) 1992-03-25 1993-03-25 耐性の誘導に有用なペプチド
AU39226/93A AU677954B2 (en) 1992-03-25 1993-03-25 Peptides useful for inducing tolerance
CA2132873A CA2132873C (fr) 1992-03-25 1993-03-25 Peptides pouvant induire la tolerance
EP93908385A EP0672134A1 (fr) 1992-03-25 1993-03-25 Peptides utilises pour l'induction de tolerance

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85731192A 1992-03-25 1992-03-25
US07/857,311 1992-03-25
US88471892A 1992-05-15 1992-05-15
US07/884,718 1992-05-15
US611693A 1993-01-15 1993-01-15
US08/006,116 1993-01-15

Publications (2)

Publication Number Publication Date
WO1993019178A2 WO1993019178A2 (fr) 1993-09-30
WO1993019178A3 true WO1993019178A3 (fr) 1993-11-25

Family

ID=27358042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/002462 WO1993019178A2 (fr) 1992-03-25 1993-03-25 Peptides utilises pour l'induction de tolerance

Country Status (7)

Country Link
EP (1) EP0672134A1 (fr)
JP (1) JPH07505365A (fr)
AU (1) AU677954B2 (fr)
CA (1) CA2132873C (fr)
IL (1) IL105153A (fr)
MX (1) MX9301675A (fr)
WO (1) WO1993019178A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120769A (en) * 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US6019972A (en) 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
WO1994027634A1 (fr) * 1993-06-02 1994-12-08 Institute For Child Health Research Peptides caches permettant d'induire une tolerance immunologique
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
AU4278296A (en) * 1994-10-25 1996-05-15 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
JP4340329B2 (ja) * 1996-03-21 2009-10-07 サーカッシア リミテッド 潜在ペプチドならびにそれらの同定方法
EP0960887B1 (fr) 1996-06-14 2007-04-25 Meiji Dairies Corporation Peptides constitues d'epitopes de lymphocytes t
US6780416B1 (en) 2000-02-18 2004-08-24 Ecole Polytechnique Federale De Lausanne Bee venom polypeptides and methods of use thereof
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
CA2744787C (fr) 2008-11-30 2019-06-11 Immusant, Inc. Compositions et procedes pour le traitement d'une maladie coeliaque
US10449228B2 (en) 2013-09-10 2019-10-22 Immusant, Inc. Dosage of a gluten peptide composition
AU2015323979A1 (en) 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006571A1 (fr) * 1989-11-03 1991-05-16 Immulogic Pharmaceutical Corporation Proteine de felin reagissant avec des lymphocytes t humains (pfrl), isolee a partir de poussieres menageres
WO1992015613A1 (fr) * 1991-02-28 1992-09-17 Immulogic Pharmaceutical Corporation Preparation amelioree d'allergenes aux phaneres de chat a des fins d'immunotherapie et utilisations de cette preparation
WO1993008280A1 (fr) * 1991-10-16 1993-04-29 Immulogic Pharmaceutical Corporation Peptides d'epitope recombine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006571A1 (fr) * 1989-11-03 1991-05-16 Immulogic Pharmaceutical Corporation Proteine de felin reagissant avec des lymphocytes t humains (pfrl), isolee a partir de poussieres menageres
WO1992015613A1 (fr) * 1991-02-28 1992-09-17 Immulogic Pharmaceutical Corporation Preparation amelioree d'allergenes aux phaneres de chat a des fins d'immunotherapie et utilisations de cette preparation
WO1993008280A1 (fr) * 1991-10-16 1993-04-29 Immulogic Pharmaceutical Corporation Peptides d'epitope recombine

Also Published As

Publication number Publication date
IL105153A (en) 1999-12-22
EP0672134A1 (fr) 1995-09-20
AU677954B2 (en) 1997-05-15
MX9301675A (es) 1993-12-01
CA2132873A1 (fr) 1993-09-30
WO1993019178A2 (fr) 1993-09-30
CA2132873C (fr) 2012-10-16
JPH07505365A (ja) 1995-06-15
IL105153A0 (en) 1993-07-08
AU3922693A (en) 1993-10-21

Similar Documents

Publication Publication Date Title
WO1993019178A3 (fr) Peptides utilises pour l'induction de tolerance
DK0590006T3 (da) Syntetiske pulmonære surfaktantpeptider
CA2169635A1 (fr) Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs
CA2025598A1 (fr) Proteines d'antigene nucleocapsidique d'hepadnavirus chimerique
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
ATE368053T1 (de) Antimikrobielle peptide
EP0284587A3 (fr) Antigènes peptides synthétiques pour la détection d'infections de HIV-1
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
EP0334244A3 (fr) Peptides antagonistes de Bradykinine
IL93397A (en) Pancreatic islet cell antigen protein or peptides, their preparation by molecular cloning, their use in the diagnosis of insulin dependent diabetes mellitus and pharmaceutical compositions comprising said antigens
EP0733071A4 (fr) Antagonistes de la chaperonine 10
WO2002044197A3 (fr) Peptides de fixation des recepteurs des cytokines
CA2083177A1 (fr) Proteines surfactantes alveolaires
EP0161007A3 (fr) Analogues de l'hexapeptide rétro-inverso C-terminal de la substance P
EP0129582A4 (fr) Peptides et proteines biologiquement actifs pour administration orale.
WO1993021321A3 (fr) EPITOPES DE LYMPHOCYTES T DES PRINCIPAUX ALLERGENES D'$i(AMBROSIA ARTEMISIIFOLIA)
KR960702754A (ko) 생리적으로 활성인 펩티드를 함유하는 질내 투여 제제(vaginal preparation containing physiologically active peptide)
AU682638B2 (en) Peptide, bronchodilator and blood flow ameliorant
CA2128407A1 (fr) Peptides synthetiques pour vaccin antirubeoleux
CA2139571A1 (fr) Peptides fixatrices du recepteur de l'interferon
CA2057612A1 (fr) Peptides selectionnes de l'antigene specifique au groupe (gag) du virus de l'immunodeficience humaine (vih), sa preparation et son utilisation
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
CA2163212A1 (fr) Composes therapeutiques
EP0317279A3 (fr) Peptides pour l'usage dans la purification du facteur-VIII
CA2163805A1 (fr) Nouveau facteur d'activation des leucocytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI HU JP KP KR NO NZ PT

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI HU JP KP KR NO NZ PT

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2132873

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993908385

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993908385

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993908385

Country of ref document: EP